Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Novel Fusion Transcripts PVT1-NSMCE2 and BF104016-NSMCE2 Resulting In Depletion Of NSMCE2 Protein In Acute Myeloid Leukemia Harboring 8q24 Amplicons

Yoshiaki Chinen, MD, Natsumi Sakamoto, Hisao Nagoshi, MD, PhD, Tomohiko Taki, MD, PhD, Satoru Kobayashi, Kazuhiro Nishida, MD, PhD, Saori Maegawa, MD, Ryuko Nakayama, MD, Miki Kiyota, MD, Shinsuke Mizutani, MD, Yuji Shimura, MD, PhD, Mio Yamamoto-Sugitani, MD, PhD, Tsutomu Kobayashi, MD, PhD, Yosuke Matsumoto, MD, PhD, Shohei Yokota, MD, PhD, Shigeo Horiike, MD, PhD, Junya Kuroda, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2013) 122 (21): 3726.

https://doi.org/10.1182/blood.V122.21.3726.3726

Published: 2013

Journal Articles

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Yuji Shimura, MD, Junya Kuroda, MD, PhD, Hisao Nagoshi, MD, Mio Yamamoto-Sugitani, MD, PhD, Tsutomu Kobayashi, MD, PhD, Miki Kiyota, MD, Ryuko Nakayama, MD, Shinsuke Mizutani, MD, Yoshiaki Chinen, MD, Natsumi Sakamoto, Yosuke Matsumoto, MD, PhD, Shigeo Horiike, MD, PhD, Masaki Ri, MD, PhD, Yukimasa Shiotsu, PhD, Shinsuke Iida, MD, PhD, Tomohiko Taki, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2012) 120 (21): 2945.

https://doi.org/10.1182/blood.V120.21.2945.2945

Published: 2012

Journal Articles

Fingolimod (FTY720) Overcomes the Resistance to Tyrosine Kinase Inhibitors Via Dual Activation of BIM and BID in Chronic Myelogenous Leukemia

Miki Kiyota, MD, Junya Kuroda, MD, PhD, Mio Yamamoto-Sugitani, MD, PhD, Yuji Shimura, MD, Ryuko Nakayama, MD, Hisao Nagoshi, MD, Shinsuke Mizutani, MD, Yoshiaki Chinen, MD, Natsumi Sakamoto, Tsutomu Kobayashi, MD, PhD, Yosuke Matsumoto, MD, PhD, Shigeo Horiike, MD, PhD, Tomohiko Taki, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2012) 120 (21): 3744.

https://doi.org/10.1182/blood.V120.21.3744.3744

Published: 2012

Journal Articles

Galectin-3 Is the Molecular Target for Overcoming Multidrug Resistance Due to the Cell Protection by Bone Marrow Leukemia Microenvironment in Chronic Myeloid Leukemia,

Mio Yamamoto, Junya Kuroda, MD, PhD, Tsutomu Kobayashi, MD, PhD, Nana Sasaki, MD, Hisao Nagoshi, Yuji Shimura, Miki Kiyota, Ryuko Nakayama, Shigeo Horiike, MD, PhD, Eishi Ashihara, MD, PhD, Kenichi Akaji, PhD, Masafumi Taniwaki, MD, PhD

Blood (2011) 118 (21): 3746.

https://doi.org/10.1182/blood.V118.21.3746.3746

Published: 2011

Journal Articles

Leukemia Microenvironment-Specific Galectin-3 Expression of Leukemic Cells Promotes Malignant Niche Formation and Bone Marrow Lodgment of Leukemic Cells in Chronic Myelogenous Leukemia

Junya Kuroda, MD, PhD, Mio Yamamoto, Eishi Ashihara, MD, PhD, Hisao Nagoshi, MD, Tsutomu Kobayashi, MD, PhD, Yosuke Matsumoto, MD, PhD, Nasa Sasaki, Yuji Shimura, Miki Kiyota, Ryuko Nakayama, Shigeo Horiike, Taira Maekawa, MD, PhD, Masafumi Taniwaki

Blood (2011) 118 (21): 1678.

https://doi.org/10.1182/blood.V118.21.1678.1678

Published: 2011

NARROW

Novel Fusion Transcripts PVT1-NSMCE2 and BF104016-NSMCE2 Resulting In Depletion Of NSMCE2 Protein In Acute Myeloid Leukemia Harboring 8q24 Amplicons

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Fingolimod (FTY720) Overcomes the Resistance to Tyrosine Kinase Inhibitors Via Dual Activation of BIM and BID in Chronic Myelogenous Leukemia

Galectin-3 Is the Molecular Target for Overcoming Multidrug Resistance Due to the Cell Protection by Bone Marrow Leukemia Microenvironment in Chronic Myeloid Leukemia,

Leukemia Microenvironment-Specific Galectin-3 Expression of Leukemic Cells Promotes Malignant Niche Formation and Bone Marrow Lodgment of Leukemic Cells in Chronic Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Novel Fusion Transcripts PVT1-NSMCE2 and BF104016-NSMCE2 Resulting In Depletion Of NSMCE2 Protein In Acute Myeloid Leukemia Harboring 8q24 Amplicons

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Fingolimod (FTY720) Overcomes the Resistance to Tyrosine Kinase Inhibitors Via Dual Activation of BIM and BID in Chronic Myelogenous Leukemia

Galectin-3 Is the Molecular Target for Overcoming Multidrug Resistance Due to the Cell Protection by Bone Marrow Leukemia Microenvironment in Chronic Myeloid Leukemia,

Leukemia Microenvironment-Specific Galectin-3 Expression of Leukemic Cells Promotes Malignant Niche Formation and Bone Marrow Lodgment of Leukemic Cells in Chronic Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only